Open Access Open Access  Restricted Access Subscription or Fee Access

Review on Drug induced hematological disorder.

Roshan B. Badhe, Samiksha Amrutkar

Abstract


Drugs have the potential to profoundly impact not just the bone marrow, but also the entire spectrum of peripheral blood cells, leading to a wide array of hematologic disorders. These pharmaceutical-induced conditions can affect white blood cells, red blood cells, platelets, and the coagulation system, posing a significant risk in modern pharmacotherapy. Among the drug-induced syndromes, some noteworthy examples include aplastic anemia, agranulocytosis, hemolytic anemia, megaloblastic anemia, thrombocytopenia, methemoglobinemia, sideroblastic anemia, and pure blood cell aplasia. These drug-related hematologic complications underscore the importance of careful monitoring and vigilant management when prescribing and using medications, as they can potentially be life-threatening.

Keywords


Drug-induced anemia, aplastic anemia, agranulocytosis, hemolytic anemia, megaloblastic anemia, thrombocytopenia, pure blood cell hypoplasia, eosinophilia. Sideroblastic anemia.

Full Text:

PDF

References


Lubran, MICHAEL M. "Hematologic side effects of drugs." Annals of Clinical & Laboratory Science 19.2 (1989): 114-121.

Scheinberg, Phillip, and Neal S. Young. "How I treat acquired aplastic anemia." Blood, The Journal of the American Society of Hematology 120.6 (2012): 1185-1196.

Brodsky, Robert A., and Richard J. Jones. "Aplastic anaemia." The Lancet 365, no. 9471 (2005): 1647-165.

A M Gewirtz, R Hoffman. Current considerations of the etiology of aplastic anemia. Crit Rev Oncol Hematol 1985; 4:1–30.

N S Young, R T Calado, and P Scheinberg. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509–19.

Roger Walker. Clinical Pharmacy and Therapeutics. 2012; 5th edition: 655-663.

G. Garratty and P. A. Arndt, An update on drug-induced immune hemolyticanemia, Immunohematology, 2007; 23(2): 105–119.

Amit Kumar, V N Jha and Nimisha. Megaloblastic Anemia – An Underdiagnosed Public Health Problem. World Journal of Pharmaceutical and Medical Research 2018,4(2), 100-101

K C Das, Das Monisha and D Mohanty, M.M Jadaon, A Gupta Megaloblastosis: from morphos tomolecules. Med PrincPract 2005; 14: (Suppl 1): 2-14.

N L Kobrinsky and N K Ramsay. Acute megaloblastic anemia induced by high-dose trimethoprim-sulfamethoxazole. Ann Intern Med 1981; 94: 780- 781.

F Magee, O’H Sullivan and S R McCann. Megaloblastosis and lowdose trimethoprim-sulfamethoxazole. Ann Intern Med 1981; 95: 657-661.

N Patel, H Vandewall, and L Tristani. A comparative evaluation of adverse platelet outcomes among Veterans’ Affairs patients receiving linezolid or vancomycin. J AntimicrobChemother 2012;67(3):725–735 13.N.James George and H Richard. AsterDruginduced thrombocyte-penia: pathogenesis, evaluation, and management. Hematology (Am SocHematolEduc Program) 2009: 153– 158

B Kenney and Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133(2): 309–31

N Frickhofen, Z J Chen, N S Young, B J Cohen, H Heimpel and J L Abkowitz. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol. 1994;87(4):818-24.

B Saikia, H Aneja, A Manchanda, R Patowary and B Barman. Carbamazepine-induced Pure Red Cell Aplasia in a Young Girl. Indian Journal of Medical Specialities Trust 2010; 1(2): 130- 133

R A Sharma, P Hiwarkar, M V Manglani and H P Muralidhar. Acquired pure red cell aplasia in a child. J Postgrad Med, 2002; 48: 37-38

Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15;106(10):3343-7.6.

Topal, Hatice, and Yasar Topal. "Toxic methemoglobinemia treated with ascorbic acid: Case report." Iranian Red Crescent Medical Journal 15, no. 12 (2013).

Alcindor, Thierry, and Kenneth R. Bridges. "Sideroblastic anaemias." British journal of haematology 116, no. 4 (2002): 733-743.

R. A. Sharp, J. G. Lowe and R. N. Johnston, “Anti-tuberculousdrugs and sideroblastic anaemia,” British Journal of Clinical Practice, 1990; 44 (12). 7 06–707.

S Ammus and A A.Yunis. Druginduced red cell dyscrasias.Blood Rev. 1989;3(2):71-82.

L A Fernandez and E Zayed.Busulfan-induced sideroblasticanemia. Am J Hematol. 1988; 28(3):199–200.

L Kandola, A J Swannell, and A HunterAcquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis.Ann Rheum Dis. 1995; 54(6): 529–530.




DOI: https://doi.org/10.37591/rrjodfdp.v10i2.1344

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production